SVR4

Atea Pharmaceuticals Reports First Quarter 2024 Financial Results and Provides Business Update

Retrieved on: 
火曜日, 5月 14, 2024
Plasma, SOC, Risk, FDA, Ageing, Electrocardiography, Week, Fast Track, HCV, Kinetics, RNA, Research, QRS, Standard of care, QT, Bemnifosbuvir, Patient, QT interval, Infection, Cardiotoxicity, SVR4, Security (finance), Second generation, Administration, COVID-19, Food, Clinical trial, Viral, Safety, Hospital, Viral load, SVR, Doctor of Philosophy, NS5A, EASL, BID, Heart rate, Tax, NS5B, Immunodeficiency, Death, Cirrhosis, PR, Development, Pharmaceutical industry

BOSTON, May 14, 2024 (GLOBE NEWSWIRE) -- Atea Pharmaceuticals, Inc. (Nasdaq: AVIR) (Atea or Company), a clinical-stage biopharmaceutical company engaged in the discovery and development of oral antiviral therapeutics for serious viral diseases, today reported financial results for the first quarter ended March 31, 2024 and provided a business update.

Key Points: 
  • BOSTON, May 14, 2024 (GLOBE NEWSWIRE) -- Atea Pharmaceuticals, Inc. (Nasdaq: AVIR) (Atea or Company), a clinical-stage biopharmaceutical company engaged in the discovery and development of oral antiviral therapeutics for serious viral diseases, today reported financial results for the first quarter ended March 31, 2024 and provided a business update.
  • Final results from the 60-patient lead-in cohort confirmed a 98% SVR4 rate across all genotypes from 58 of 59 patients.
  • Topline results from all patients enrolled in the Phase 2 study are anticipated in the second half of 2024.
  • In April 2024, Atea presented Phase 1 data showing that bemnifosbuvir does not alter cardiac repolarization.

Atea Pharmaceuticals Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update

Retrieved on: 
水曜日, 2月 28, 2024
Fast Track, HCV, BID, Patient, Week, Research, Infection, Tax, Doctor of Philosophy, NS5A, FDA, Food, Security (finance), SVR4, Kinetics, Immunodeficiency, Hospital, Standard of care, Viral, Cirrhosis, Interim, Prevalence, Safety, COVID-19, Contraindication, Death, Administration, Atea, Bemnifosbuvir, Risk, DSMB, Second generation, Development, Ageing, SOC, SVR, Viral load, Pharmaceutical industry

BOSTON, Feb. 28, 2024 (GLOBE NEWSWIRE) -- Atea Pharmaceuticals, Inc. (Nasdaq: AVIR) (Atea or Company), a clinical-stage biopharmaceutical company engaged in the discovery and development of oral antiviral therapeutics for serious viral diseases, today reported financial results for the fourth quarter and full year ended December 31, 2023 and provided a business update.

Key Points: 
  • Enrollment of the remainder of this study is ongoing with topline results anticipated in the second half of 2024,” continued Dr. Sommadossi.
  • Final results from the 60 patient lead-in cohort confirmed a 98% SVR4 rate across GT from 58 of 59 patients.
  • Final SVR12 results from all patients enrolled in the Phase 2 study are anticipated in the second half of 2024.
  • Cash, Cash Equivalents and Marketable Securities: $578.1 million at December 31, 2023 compared to $646.7 million at December 31, 2022.

Atea Pharmaceuticals Announces Positive Initial Data from Phase 2 Study for Hepatitis C Virus (HCV) and Significant Enrollment Milestone for Phase 3 SUNRISE-3 Trial for COVID-19

Retrieved on: 
月曜日, 1月 8, 2024
Patient, DSMB, Immunodeficiency, SVR4, Contraindication, Infection, Arm, BID, Bemnifosbuvir, RZR, Ageing, Hepatitis, Incidence, Viral load, Doctor of Philosophy, Cirrhosis, Standard of care, Hospital, Risk, HCV, Rest, Viral, Death, COVID-19, Safety, SOC, Enrollment, Kinetics, Pharmaceutical industry

BOSTON, Jan. 08, 2024 (GLOBE NEWSWIRE) -- Atea Pharmaceuticals, Inc. (Nasdaq: AVIR) (“Atea”), a clinical-stage biopharmaceutical company engaged in the discovery and development of oral antiviral therapeutics for serious viral diseases, today announced the achievement of two significant clinical milestones from its Hepatitis C Virus (HCV) and COVID-19 programs. The Company reported positive initial data from the first 52 patients in the lead-in cohort of its Phase 2 combination 8-week study of bemnifosbuvir and ruzasvir (RZR) for the treatment of HCV. Additionally, Atea has enrolled more than 650 patients in the monotherapy arm of its Phase 3 SUNRISE-3 trial for the treatment of COVID-19, and enrollment continues with the current wave. This enrollment milestone allows for the first interim analysis of the study by the DSMB, which is expected this March.

Key Points: 
  • This enrollment milestone allows for the first interim analysis of the study by the DSMB, which is expected this March.
  • “We are excited to share that the initial data from the Phase 2 combination 8-week study showed a 98% SVR4, which exceeds our efficacy criterion of >90% for continuing the study.
  • Preliminary data are being presented as available, with SVR4 data currently available from 52 of the 60 lead-in patients.
  • The primary endpoint of the trial is all-cause hospitalization or death through Day 29 post-treatment in the monotherapy arm in 2,200 patients.